Literature DB >> 24335183

Overexpression of the pp32r1 (ANP32C) oncogene or its functional mutant pp32r1Y140H confers enhanced resistance to FTY720 (Finguimod).

Salma Buddaseth1, Wiebke Göttmann1, Rainer Blasczyk1, Trevor Huyton1.   

Abstract

pp32r1 (ANP32C) is oncogenic and has been shown to be overexpressed in tumors of the breast, prostate, and pancreas. In this work we show that pp32 family proteins are able to bind to the sphingosine analog FTY720 (Finguimod). Molecular docking studies highlight that a conserved residue F136 is likely to be a key determinant of the FTY720 binding site on the pp32 leucine-rich repeat domain. Transduction of the renal carcinoma cell line ACHN or cervical cancer cell line HeLa with lentivirus expressing the oncogenic family member pp32r1 or a pp32r1Y140H functional mutant illustrated an enhanced resistance to FTY720 induced apoptosis. These findings highlight that certain cancers overexpressing pp32r1 or pp32r1 mutants are likely to demonstrate enhanced resistance to FTY720 treatment.

Entities:  

Keywords:  FTY720; cancer; cell cycle; pp32

Mesh:

Substances:

Year:  2013        PMID: 24335183      PMCID: PMC3974830          DOI: 10.4161/cbt.27307

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  41 in total

1.  Phosphorylated retinoblastoma protein complexes with pp32 and inhibits pp32-mediated apoptosis.

Authors:  Onikepe Adegbola; Gary R Pasternack
Journal:  J Biol Chem       Date:  2005-02-16       Impact factor: 5.157

2.  I1PP2A and I2PP2A. Two potent protein phosphatase 2A-specific inhibitor proteins.

Authors:  M Li; Z Damuni
Journal:  Methods Mol Biol       Date:  1998

3.  Early induction of apoptosis in androgen-independent prostate cancer cell line by FTY720 requires caspase-3 activation.

Authors:  J D Wang; S Takahara; N Nonomura; N Ichimaru; K Toki; H Azuma; K Matsumiya; A Okuyama; S Suzuki
Journal:  Prostate       Date:  1999-06-15       Impact factor: 4.104

4.  FTY720 produces caspase-independent cell death of acute lymphoblastic leukemia cells.

Authors:  Craig T Wallington-Beddoe; John Hewson; Kenneth F Bradstock; Linda J Bendall
Journal:  Autophagy       Date:  2011-07-01       Impact factor: 16.016

5.  Structure of pp32, an acidic nuclear protein which inhibits oncogene-induced formation of transformed foci.

Authors:  T H Chen; J R Brody; F E Romantsev; J G Yu; A E Kayler; E Voneiff; F P Kuhajda; G R Pasternack
Journal:  Mol Biol Cell       Date:  1996-12       Impact factor: 4.138

6.  FTY720 (fingolimod) sensitizes prostate cancer cells to radiotherapy by inhibition of sphingosine kinase-1.

Authors:  Dmitri Pchejetski; Torsten Bohler; Leyre Brizuela; Lysann Sauer; Nicolas Doumerc; Muriel Golzio; Vishal Salunkhe; Justin Teissié; Bernard Malavaud; Jonathan Waxman; Olivier Cuvillier
Journal:  Cancer Res       Date:  2010-10-19       Impact factor: 12.701

7.  FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.

Authors:  Paolo Neviani; Ramasamy Santhanam; Joshua J Oaks; Anna M Eiring; Mario Notari; Bradley W Blaser; Shujun Liu; Rossana Trotta; Natarajan Muthusamy; Carlo Gambacorti-Passerini; Brian J Druker; Jorge Cortes; Guido Marcucci; Ching-Shih Chen; Nicole M Verrills; Denis C Roy; Michael A Caligiuri; Clara D Bloomfield; John C Byrd; Danilo Perrotti
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

8.  Identification of a functional mutation in pp32r1 (ANP32C).

Authors:  G John Kochevar; Jonathan R Brody; ShriHari S Kadkol; Kathleen M Murphy; Gary R Pasternack
Journal:  Hum Mutat       Date:  2004-06       Impact factor: 4.878

9.  AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility.

Authors:  Garrett M Morris; Ruth Huey; William Lindstrom; Michel F Sanner; Richard K Belew; David S Goodsell; Arthur J Olson
Journal:  J Comput Chem       Date:  2009-12       Impact factor: 3.376

10.  pp32 (ANP32A) expression inhibits pancreatic cancer cell growth and induces gemcitabine resistance by disrupting HuR binding to mRNAs.

Authors:  Timothy K Williams; Christina L Costantino; Nikolai A Bildzukewicz; Nathan G Richards; David W Rittenhouse; Lisa Einstein; Joseph A Cozzitorto; Judith C Keen; Abhijit Dasgupta; Myriam Gorospe; Gregory E Gonye; Charles J Yeo; Agnieszka K Witkiewicz; Jonathan R Brody
Journal:  PLoS One       Date:  2010-11-29       Impact factor: 3.240

View more
  6 in total

1.  Cracking the ANP32 whips: important functions, unequal requirement, and hints at disease implications.

Authors:  Patrick T Reilly; Yun Yu; Ali Hamiche; Lishun Wang
Journal:  Bioessays       Date:  2014-08-25       Impact factor: 4.345

Review 2.  Switching the sphingolipid rheostat in the treatment of diabetes and cancer comorbidity from a problem to an advantage.

Authors:  Nikolas K Haass; Najah Nassif; Eileen M McGowan
Journal:  Biomed Res Int       Date:  2015-03-19       Impact factor: 3.411

3.  The expression and distributions of ANP32A in the developing brain.

Authors:  Shanshan Wang; Yunliang Wang; Qingshan Lu; Xinshan Liu; Fuyu Wang; Xiaodong Ma; Chunping Cui; Chenghe Shi; Jinfeng Li; Dajin Zhang
Journal:  Biomed Res Int       Date:  2015-03-19       Impact factor: 3.411

4.  The phosphorylated form of FTY720 activates PP2A, represses inflammation and is devoid of S1P agonism in A549 lung epithelial cells.

Authors:  Md Mostafizur Rahman; Laura Prünte; Leonard F Lebender; Brijeshkumar S Patel; Ingrid Gelissen; Philip M Hansbro; Jonathan C Morris; Andrew R Clark; Nicole M Verrills; Alaina J Ammit
Journal:  Sci Rep       Date:  2016-11-16       Impact factor: 4.379

Review 5.  The emerging role of FTY720 (Fingolimod) in cancer treatment.

Authors:  Christopher White; Heba Alshaker; Colin Cooper; Matthias Winkler; Dmitri Pchejetski
Journal:  Oncotarget       Date:  2016-04-26

Review 6.  Protein phosphatase 2A (PP2A): a key phosphatase in the progression of chronic obstructive pulmonary disease (COPD) to lung cancer.

Authors:  Cassandra P Nader; Aylin Cidem; Nicole M Verrills; Alaina J Ammit
Journal:  Respir Res       Date:  2019-10-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.